• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2015 News Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
Jun 29, 2015EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx
MARIETTA, Ga., June 29, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that its Chairman and CEO, Parker H. "Pete" Petit, has been awarded the Lifetime Achievement Award in the EY Entrepreneur Of The Year® 2015 ... 
Printer Friendly Version
May 27, 2015MiMedx To Present At The Jefferies 2015 Global Healthcare Conference
MARIETTA, Ga., May 27, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the Jefferies 2015 Global Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CE... 
Printer Friendly Version
May 19, 2015MiMedx To Present At The 12th Annual Craig-Hallum Institutional Investor Conference
MARIETTA, Ga., May 19, 2015 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the 12th Annual Craig-Hallum Institutional  Investor Conference in Minneapolis, Minnesota.  Parker H. "Pete" P... 
Printer Friendly Version
May 13, 2015MiMedx Announces Publication On CollaFix™, The Company's Next Technology Platform To Be Commercialized
COLLAFIX FIBROUS COLLAGEN SCAFFOLD MIMICS THE NATIVE TISSUE BIOMECHANICS OF TENDON/LIGAMENT TISSUES MARIETTA, Ga., May 13, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that the publication of its peer-revie... 
Printer Friendly Version
May 08, 2015MiMedx Receives 2015 Innovative Technology Award from Novation
MiMedx also Receives National Agreement with Novation MARIETTA, Ga., May 8, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Novation has recognized MiMedx as a recipient of Novation's Innovative Tec... 
Printer Friendly Version
Apr 29, 2015Comparative Effectiveness Study Exhibiting Superior Outcomes Of MiMedx EpiFix® Receives Award At SAWC Conference
Oral and Poster Abstracts Demonstrate EpiFix® allografts shown to: increase healing rates, require fewer grafts and at less cost per healed wound, have greater reductions in wound size, be more clinically and cost effective, involve easier handling and application, and be well tolerated by patients MARIETTA, Ga., April 29, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG) announced today that one oral abstract and four poster abstracts showing the Company's EpiFix® allografts to be clini... 
Printer Friendly Version
Apr 27, 2015MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance
Company Records Revenue of $40.8 million and Net Income of $4.1 million MARIETTA, Ga., April 27, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the first quarter of 2015. The ... 
Printer Friendly Version
Apr 23, 2015MiMedx To Present At The 40th Annual Deutsche Bank Securities Healthcare Conference
MARIETTA, Ga., April 23, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the 40th Annual Deutsche Bank Securities Healthcare Conference in Boston, Massachusetts.  Parker H. "Pete" Pe... 
Printer Friendly Version
Apr 13, 2015MiMedx Announces Expansion Of Health Plan Coverage
53 Million Covered Lives From 27 New Health Plans Are Added During First Quarter Of 2015 MARIETTA, Ga., April 13, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today the updated status of the Company's payer... 
Printer Friendly Version
Apr 13, 2015MiMedx Reports Record First Quarter 2015 Revenue of $40.8 Million
Q1 2015 REVENUE REPRESENTS A 108% INCREASE OVER Q1 2014 MARIETTA, Ga., April 13, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, pre-announced today its record revenue results for the first quarter of 2015. First Qu... 
Printer Friendly Version
Apr 03, 2015MiMedx Group, Inc. Announces Release Date for 2015 First Quarter Results
MARIETTA, Ga., April 3, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the first quarter ended March 31, 2015, will be released before the opening of the market on Tuesday, April 28, 2... 
Printer Friendly Version
Apr 01, 2015MiMedx To Present At The 14th Annual Needham Healthcare Conference
MARIETTA, Ga., April 1, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the 14th Annual Needham Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO... 
Printer Friendly Version
Mar 23, 2015Government Declines to Intervene in Action Against MiMedx
MARIETTA, Ga., March 23, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it has received notice from the Department of Justice that it has declined at this time to intervene in the qui tam action that... 
Printer Friendly Version
Mar 17, 2015MiMedx to Present at 3rd Annual Regen Med Investor Day
MARIETTA, Ga., March 17, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Deborah Dean, Executive Vice President, and Frank Burrows, Vice President, will represent the Company at the 3rd Annual Regen M... 
Printer Friendly Version
Mar 16, 2015MiMedx To Present At Canaccord's 10th Annual Musculoskeletal Conference
THE COMPANY TO EXHIBIT AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MARIETTA, Ga., March 16, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at C... 
Printer Friendly Version
Feb 26, 2015MiMedx Announces 2014 Record Revenue and First Full Year Operating Profit
Company Records Revenue of $118.2 million, Operating income of $7.1 million and Net Income of $6.2 million MARIETTA, Ga., Feb. 26, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for ... 
Printer Friendly Version
Feb 04, 2015MiMedx Announces Release Date For 2014 Full Year Results
MARIETTA, Ga., Feb. 4, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2014, will be released before the opening of the market on Thursda... 
Printer Friendly Version
Feb 03, 2015MiMedx Withdraws Complaint Against Organogenesis Without Prejudice To Focus On Investigation
MARIETTA, Ga., Feb. 3, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced that it has voluntarily withdrawn its tortious interference lawsuit against Organogenesis, Inc., without prejudice.  MiMedx has expressly re... 
Printer Friendly Version
Jan 12, 2015MiMedx Announces over 30 National Account Contracts
CONTRACTS COVER MORE THAN 4,000 U.S. HOSPITALS MARIETTA, Ga., Jan. 12, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that the status of the Company's National Account contracts with Group Purchasing O... 
Printer Friendly Version
Jan 12, 2015MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts
$118.2 MILLION FULL YEAR 2014 REVENUE IS DOUBLE 2013 AND $39.6 MILLION Q4 2014 REVENUE IS 120% INCREASE OVER Q4 2013 MARIETTA, Ga., Jan. 12, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record re... 
Printer Friendly Version
Jan 06, 2015MiMedx Announces $10 Million Increase to Stock Repurchase Program
MARIETTA, Ga., Jan. 6, 2015 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its Board of Directors increased the Company's authorization for its share repurchase plan from $10,000,000 to $20,000,000.  The $20,... 
Printer Friendly Version

Products

CONTACT US

888.543.1917